- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04410874
Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer (MUSIC-01)
MVA-BN Imvamune Smallpox Vaccine Virus for Treatment of Basal Cell Carcinoma, Squamous Cell Carcinomas
Study Overview
Status
Intervention / Treatment
Detailed Description
One of the main ways cancer is able to develop is by hiding or evading our immune system which usually detects and kills potential tumor cells. Once cancer has developed the ability to evade the immune system it can continue to grow and become a tumor. One potential strategy currently being researched, called immunotherapy, uses viruses to stimulate an immune response which attacks the tumor.
Imvamune is a live, non-replicating virus used in Canada to vaccinate adults and children against smallpox. It is safe to use in immunosuppressed patients because the virus is unable to replicate and spread past the first infected cell. This makes the Imvamune vaccine a viable candidate for immunotherapy in immunosuppressed patients who are at a much higher (up to 60x) risk of developing non-melanoma skin cancers.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Ivan V. Litvinov, M.D., Ph.D
- Phone Number: 76140 514-934-1934
- Email: ivan.litvinov@mcgill.ca
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada
- McGill University Health Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects must have histologically confirmed, BCC and/or SCC tumors located on the chest, back, thigh, or arm/forearm.
- Presence of clinically documented disease. Skin tumor should measure at least 10 mm in size and should be no larger than 5 cm in any axes. There should be no clinical suspicion of metastasis (i.e. no lymphadenopaties and no systemic symptoms).
- Age > 18 years.
- Subjects must have a documented ECOG performance status of 0 or 1.
- Subjects could be treatment naive or could have had previous surgery or radiation
- Subjects may have had prior radiation therapy. A minimum of 28 days (4 weeks) must have elapsed between the last dose of radiation and date of registration (14 days for a single palliative fraction of radiation to a non-target lesion). Subjects must have recovered from any acute toxic effects from radiation prior to registration (unless grade 1, irreversible and considered not clinically significant).
- Previous surgery is permitted. A minimum of 28 days (4 weeks) must have elapsed between any major surgery and date of registration (7 days for minor surgery), provided that wound healing has occurred
- Each subject must sign a consent form prior to registration/at registration and prior to tests which are study specific.
- Subjects must be accessible for treatment and follow-up. Subjects registered on this trial must be treated and followed at the McGill University Health Centre (MUHC) or McGill Affiliated/other participating hospitals
- Laboratory requirements (must be done within 7 days prior to registration or at time of registration) as follows:
- White blood cell count ≥3.0x10^9/L
- absolute neutrophils ≥1.5x10^9/L
- hemoglobin ≥100g/L
- platelets ≥75x10^9/L
- INR ≤1.2
- bilirubin ≤1.5x upper normal limit
- AST and ALT ≤3.0x upper normal limit
- serum creatinine ≤1.5x upper normal limit (or creatinine clearance of ≥60mL/min)
Exclusion Criteria:
- Cancers located on cosmetically/functionally important areas (i.e. face, neck, genitalia, hands, feet, and lower legs).
- Tumor larger than 5 cm in size (any axes).
- Metastatic disease (or suspicion of metastasis).
- Tumors arising as part of a genetic syndrome (i.e., Bazex-Dupré-Christol, Basal Cell Nevus Syndrome, Rombo syndromes for BCC or Xeroderma Pigmentosa, Ferguson Smith, Grzybowski, Muir-Tore syndromes for SCC).
- Immunosuppressed individuals (e.g. organ transplant recipients, patient with inherited immunodeficiencies, HIV+ individuals or individuals receiving immunosuppressive medications for other reasons).
- Individuals that are not able or willing to sign an informed consent.
- Subjects with history of other active or current malignancies requiring active treatment.
- Patients undergoing concurrent treatments with other anti-cancer therapy or other investigational agents.
- Subjects with prior treatment with Imvamune
- Subjects with serious illness or medical condition that would not permit management
- Subjects with uncontrolled pre-existing cardiovascular conditions and/or symptomatic cardiac dysfunction.
- Pregnant or lactating women. Men or women of childbearing potential who do not agree to use adequate contraception while on trial and 6 weeks following the trial.
- Subjects using anti-viral medications, steroids, immunosuppressive agents, or immunization (including the flu shot) within 14 days prior to registration. Patients who are at high risk of influenza infection (65 years and older, people of any age with certain chronic medical conditions (such as asthma, diabetes, or heart disease), pregnant women and children younger than 5 years), and who have not received an influenza vaccination during the flu season (i.e., October to May).
- Subjects with a condition that could have resulted in splenic dysfunction (e.g. splenectomy, sickle cell anemia, radiation to the spleen ≥ 20Gy, congenital asplenism).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Imvamune
Imvamune vaccine to be administered intratumorally at one of three doses on Days 0 and 4 of the study
|
Imvamune vaccine to be administered (via injection) intratumorally at one of three doses (1x10^7, 1x10^8, or 4x10^8 PFU) twice, 4 days apart (first injection on Day 0 of the study and second injection on Day 4)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD)
Time Frame: 25 days
|
The MTD will be defined as the dose at which 2 or more patients experience a grade 3 or 4 adverse event (as defined by NCI Common Terminology Criteria for Adverse Events version 5.0) that is at least "probably related" to the study drug (ex: dose limiting toxicity).
|
25 days
|
Objective Tumor Response Rate (ORR)
Time Frame: 25 days
|
Clinical and histological evaluation of the tumor to assess the development of immunity against BCC and/or SCC tumors or their protein markers.
|
25 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Viral load in NMSC tumours
Time Frame: 25 days
|
Ability to detect viral infection in the tumor.
|
25 days
|
Number of T cells/concentration of antigen specific antibodies
Time Frame: 25 days
|
Ability to elicit increased immunological T/NKT cell mediated response, and antibody response against the tumor.
|
25 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ivan V Litvinov, M.D., Ph.D, McGill University Health Centre/Research Institute of the McGill University Health Centre
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Squamous Cell
- Neoplasms, Basal Cell
- Carcinoma
- Carcinoma, Squamous Cell
- Skin Neoplasms
- Carcinoma, Basal Cell
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antiviral Agents
- Immunologic Factors
- Vaccines
- Smallpox and monkeypox vaccine modified vaccinia ankara-bavarian nordic
Other Study ID Numbers
- 2020-4599
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Basal Cell Carcinoma
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell Carcinoma | BCC | BCC - Basal Cell Carcinoma | Basal Cell CancerUnited States
-
MediWound LtdRecruitingNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University of MiamiCompletedNodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
Christopher ZacharyRecruitingBasal Cell Carcinoma | Nodular Basal Cell Carcinoma | Superficial Basal Cell CarcinomaUnited States
-
University Hospital, BordeauxCompletedLocally Advanced Basal Cell Carcinoma | Metastatic Basal Cell CarcinomaFrance
-
Seton Healthcare FamilyUniversity of Texas at Austin; Dell Medical School at The University of Texas...WithdrawnBasal Cell Carcinoma (BCC) | Squamous Cell Carcinoma (SCC)
-
Biofrontera Bioscience GmbHActive, not recruitingSuperficial Basal Cell CarcinomaUnited States
-
Maastricht University Medical CenterRadboud University Medical Center; Catharina Ziekenhuis EindhovenCompletedSuperficial Basal Cell CarcinomaNetherlands
-
Maastricht University Medical CenterActive, not recruitingNodular Basal Cell CarcinomaNetherlands
-
Kavita SarinNational Institutes of Health (NIH); Medivir; American Skin AssociationCompletedSkin Basal Cell CarcinomaUnited States
Clinical Trials on Imvamune
-
Bavarian NordicCompleted
-
National Institute of Allergy and Infectious Diseases...Completed
-
Bavarian NordicNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Bavarian NordicNational Institute of Allergy and Infectious Diseases (NIAID)CompletedDermatitis, Atopic | Hay FeverGermany
-
Bavarian NordicCompleted
-
Bavarian NordicNational Institute of Allergy and Infectious Diseases (NIAID)CompletedAtopic DermatitisUnited States, Mexico
-
Bavarian NordicNational Institutes of Health (NIH)Completed
-
Bavarian NordicNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Bavarian NordicNational Institutes of Health (NIH)CompletedHIV InfectionsUnited States, Puerto Rico